eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Original paper

Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study

Nansheng Yu
1
,
Hongyu Luo
2
,
Donglong Liang
1
,
Na Lu
1

1.
Department of Dermatology, Affiliated Shunde Hospital of Guangzhou Medical University, China
2.
Department of Dermatology, The Fifth Affiliated Hospital of Southern Medical University, China
Adv Dermatol Allergol 2021; XXXVIII (1): 69-74
Online publish date: 2021/03/10
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Sublingual immunotherapy (SLIT) has been shown to be efficacious in patients with airway allergic diseases. However, less data have been demonstrated to show the efficacy of SLIT in patients with atopic dermatitis (AD). Aim: This study is to evaluate, in a randomized controlled study, the effect of SLIT with house dust mite (HDM) in patients with mild–moderate AD.

Material and methods
AD patients aged 4 to 60 years with a Scoring Atopic Dermatitis (SCORAD) score of 7–40 and sensitization to HDM were enrolled in the study. SLIT or control treatment was given for 24 months. SCORAD, visual analog scale (VAS) score were recorded at 6, 12, 24 month, and rescue medications were required to be recorded in the diary card. A serum level of specific IgE was tested at 24-month treatment.

Results
Ninety-six patients were enrolled, and forty-eight were allocated to SLIT. Thirty-nine patients in the SLIT group and thirty-eight patients in the control group completed the study. The patients in the SLIT group had significantly decreased ∆SCORAD, VAS and rescue medication score from 12 months’ treatment compared with the control group (p < 0.05). At 24 months of treatment, no significant change of specific IgE (p < 0.05) was observed in both groups. No severe adverse events were reported during the treatment.

Conclusions
Two years’ SLIT to HDM significantly improved the clinical symptoms and reduced drug use in patients with mild–moderate AD. SLIT may represent an additional therapeutic tool for the treatment of AD in properly selected patients.

keywords:

sublingual immunotherapy, atopic dermatitis, house dust mite

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe